Cryoport vs Lifecore Biomedical
CYRX and LFCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and LFCR compare
Cryoport is the larger company, worth 4.1 times as much as Lifecore Biomedical ($1.0B against $243M).
Cryoport grew revenue faster over the last twelve months (11.8% versus 0.47% for Lifecore Biomedical).
Cryoport keeps more of each dollar of sales as profit, with a net margin of −21.5% compared with −30.0% at Lifecore Biomedical.
Cryoport scores higher on the StockData Score (10 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | LFCR |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $243M |
| Share price | $19.89 | $6.42 |
| Change, 1 year | 125% | −21.9% |
| Change, 5 years | −72.5% | −32.3% |
| Beta (5Y) | 1.92 | 1.04 |
| Employees | 738 | 382 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.2× | 1.9× (better) |
| P/B | 2.1× | – |
| FCF yield | −1.9% (better) | −5.6% |
| Fair value | $15.89 | – |
| Margin of safety | −25.2% | – |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | 0.47% |
| Revenue growth, 5Y average | 17.5% (better) | −4.2% |
| Net income growth (TTM) | −158% (better) | −422% |
| EPS growth (TTM) | −178% (better) | −485% |
| Profitability | ||
| Gross margin | 46.9% (better) | 31.3% |
| Operating margin | −20.0% | −13.4% (better) |
| Net margin | −21.5% (better) | −30.0% |
| FCF margin | −9.8% (better) | −10.6% |
| Return on equity | −8.3% | – |
| Return on invested capital | −32.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −18.3× | −0.8× (better) |
| Current ratio | 2.04 | 3.84 (better) |
| Altman Z-score | 1.38 (better) | −0.52 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −9.8% |
| Shareholder yield | 0.00% (better) | −9.8% |
| Ownership | ||
| Held by institutions | 93.9% | 67.1% |
| Held by insiders | 3.6% | 46.1% |
| Insider net buying, 12 months | −$6.3M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.1% | 8.4% |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- LFCR stock overview
- LFCR income statement
- LFCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.